The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...

Indigo Ag has hired a new chief financial officer, while a biotech developing a potential epilepsy drug got a Series A as ...

Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the oncology-focused platform company’s decision to file for bankruptcy. Notable's ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare ...

Boehringer Ingelheim partners with the WHO Foundation to financially support WHO’s Fourteenth General Programme of Work (2025 to 2028). Credit: PeopleImages.com – Yuri A/Shutterstock. Boehringer ...

GSK to pay $2.2 billion to settle 93% of Zantac-related lawsuits. GSK targets £38 billion in sales by 2031, but market estimates fall short at £35.7 billion These cases account for 93% of the ...

Around £2billion was added to the value of GSK after the pharmaceuticals giant agreed a £1.7billion settlement over claims that its heartburn medicine Zantac caused cancer. Shares rose 3.2 per ...

GSK agreed to pay $2.2 billion to settle approximately 80,000 lawsuits in U.S. courts over claims its heartburn drug, Zantac, caused cancer. The settlements account for 93% of all cases and were ...

UK pharmaceutical giant, GSK said it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.

The UK based drug firm GSK has agreed to pay up to $2.2bn (£1.7bn; €2bn) to settle claims that the heartburn drug ranitidine (previously marketed in the US as Zantac) caused cancer. The deal, ...

"GSK today announced that it has reached agreements with 10 plaintiff firms who together represent 93 per cent (approximately 80,000) of the Zantac state court product liability cases pending against ...

Pfizer has agreed to settle most of the Zantac cases against it in state court, according to its most recent financial statement, and Sanofi in April announced that it was settling about 4,000 cases.